AstraZeneca PLC (AZN) EPS Basic: 6.64
Is AstraZeneca PLC’s EPS basic high or low?
AstraZeneca PLC's EPS basic of 6.64 is 130% above its 5-year average of 2.89, near the high end of its 5-year range (0.08–6.64).
49.72% above its 12-month average of 4.43.
AZN EPS Basic Chart
AZN Average EPS Basic Chart
AZN Current vs Average EPS Basic Chart
AZN EPS Basic Metrics
EPS BASIC
6.64
EPS BASIC AVG TTM
4.43
EPS BASIC AVG 3Y
3.70
EPS BASIC AVG 5Y
2.89
EPS BASIC AVG 10Y
2.49
EPS BASIC AVG 15Y
3.02
EPS BASIC AVG 20Y
3.25
CURRENT VS TTM AVG
+49.72%
CURRENT VS 3Y AVG
+79.46%
CURRENT VS 5Y AVG
+130.02%
CURRENT VS 10Y AVG
+166.37%
CURRENT VS 15Y AVG
+119.69%
CURRENT VS 20Y AVG
+104.28%
AstraZeneca PLC EPS Basic Formula & Definition
EPS Basic is earnings per common share before the effect of potentially dilutive securities. It shows how much profit is attributable to each current common share.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EPS Basic FAQ
- What is the EPS basic for AstraZeneca PLC (AZN)?
- The EPS basic for AZN stock is 6.64.
- Is AstraZeneca PLC's EPS basic high or low?
- AstraZeneca PLC's EPS basic of 6.64 is 130% above its 5-year average of 2.89, near the high end of its 5-year range (0.08–6.64).
- What is the TTM average EPS basic for AstraZeneca PLC (AZN)?
- The TTM average EPS basic for AZN stock is 4.43.
- What is the 3Y average EPS basic for AstraZeneca PLC (AZN)?
- The 3Y average EPS basic for AZN stock is 3.70.
- What is the 5Y average EPS basic for AstraZeneca PLC (AZN)?
- The 5Y average EPS basic for AZN stock is 2.89.
- What is the 10Y average EPS basic for AstraZeneca PLC (AZN)?
- The 10Y average EPS basic for AZN stock is 2.49.
- What is the 15Y average EPS basic for AstraZeneca PLC (AZN)?
- The 15Y average EPS basic for AZN stock is 3.02.
- What is the 20Y average EPS basic for AstraZeneca PLC (AZN)?
- The 20Y average EPS basic for AZN stock is 3.25.
AstraZeneca PLC EPS Basic History
| DATE | EPS BASIC |
|---|---|
| 2025-12-31 | 6.60 |
| 2024-12-31 | 2.27 |
| 2023-12-31 | 3.81 |
| 2022-12-31 | 2.12 |
| 2021-12-31 | 0.08 |
| 2020-12-31 | 2.44 |
| 2019-12-31 | 1.03 |
| 2018-12-31 | 1.70 |
| 2017-12-31 | 2.37 |
| 2016-12-31 | 2.77 |
| 2015-12-31 | 2.23 |
| 2014-12-31 | 0.98 |
| 2013-12-31 | 2.04 |
| 2012-12-31 | 4.99 |
| 2011-12-31 | 7.33 |
| 2010-12-31 | 5.60 |
| 2009-12-31 | 5.19 |
| 2008-12-31 | 4.20 |
| 2007-12-31 | 3.74 |
| 2006-12-31 | 3.86 |
| 2005-12-31 | 2.91 |
| 2004-12-31 | 218.00 |
| 2003-12-31 | 178.00 |
| 2002-12-31 | 1.64 |
| 2001-12-31 | 1.65 |
| 2000-12-31 | 1.43 |
| 1999-12-31 | 0.64 |
| 1998-12-31 | 1.47 |
| 1997-12-31 | 1.27 |
| 1996-12-31 | 1.16 |
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot